GW2580-d6
Product Specifications
UNSPSC Description
GW2580-d6 is the deuterium labeled GW2580. GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling[1].
Target Antigen
c-Fms; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Others;Protein Tyrosine Kinase/RTK
Field of Research
Inflammation/Immunology; Cancer
Purity
98.36
Solubility
DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
NC1=NC(N)=C(CC2=CC(OC([2H])([2H])[2H])=C(OCC3=CC=C(OC([2H])([2H])[2H])C=C3)C=C2)C=N1
Molecular Weight
372.45
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Conway JG, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83.|[3]Priceman SJ, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010 Feb 18;115(7):1461-71|[4]Conway JG, et al. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J Pharmacol Exp Ther. 2008 Jul;326(1):41-50.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Clinical Information
No Development Reported
CAS Number
2733770-48-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CST 77596S 100 µL
Mouse (E1D5H) Monoclonal Antibody IgG3 Isotype Control (Alexa Fluor® 647 Conjugate)
Ask
View Details